MISSISSAUGA, On, June 4, 2012 /PRNewswire/ - Covalon Technologies Ltd. (the
"Company" or "Covalon") (TSXV: COV), an advanced healthcare company,
today announced that it is presenting its latest breakthrough
antimicrobial products, including the recently United States FDA
cleared IV Clear, at the 2012 Association for Professionals in
Infection Control and Epidemiology, Educational Conference and
International Meeting ("APIC") from June 4 to 6 in San Antonio, Texas.
Covalon will be showcasing its latest products such as ColActive® Plus
Ag, which is cleared for use by the FDA in the management of diabetic
ulcers and other chronic wounds, IV Clear antimicrobial silicone
adhesive dressing for vascular access and SurgiClear, its unique
antimicrobial transparent silicone adhesive surgical dressing. Covalon
will also present several vascular access, urological and implantable
medical devices coated with Covalon's antimicrobial CovaCoat
"APIC 2012 is a great opportunity for Covalon's North American,
European, and Asian customers, medical professionals, and potential
business partners to see our innovative infection prevention and
control products" said Brian Pedlar, Covalon's Chief Executive Officer.
APIC's Annual Educational Conference and International Meeting is one of
the largest annual gatherings of infection preventionists in the world.
It showcases the latest innovative products, technologies and services
and provides unparalleled opportunities to engage with infection
prevention experts. The 39th Annual Educational Conference &
International Meeting brings together professionals from across the
healthcare continuum, with more than 200 companies and 2,700 attendees
expected at this year's event.
To learn more about Covalon's products and services, please visit us at
booth #235 in the Henry B. Gonzalez Convention Center in San Antonio,
Texas from June 4 to 6, 2012 or contact Covalon directly:
Covalon Technologies Ltd. researches, develops and commercializes new
healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the
advanced healthcare needs of medical device companies, healthcare
providers and individual consumers. Covalon's technologies are used to
prevent, detect and manage medical conditions in specialty areas such
as wound care, tissue repair, infection control, disease management,
medical device coatings and biocompatibility. To learn more about
Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will",
"should", "could" or "might" occur or be achieved and other similar
expressions. These forward-looking statements involve risk and
uncertainties, including the difficulty in predicting product
approvals, acceptance of and demands for new products, the impact of
the products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which could
cause results, performance, or achievements to differ materially from
the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to
the Company. Investors should consult the Company's ongoing quarterly
filings for additional information on risks and uncertainties relating
to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements whether as
a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.